Advancements in Clinical Evaluation and Regulatory Frameworks for AI-Driven Software as a Medical Device (SaMD)

人工智能驱动的医疗器械软件(SaMD)临床评估和监管框架的进展

阅读:1

Abstract

Owing to the rapid progress in artificial intelligence (AI) and the widespread use of generative learning, the problem of sparse data has been solved effectively in various research fields. The application of AI technologies has resulted in important transformations in healthcare, particularly in radiology. To ensure the high quality, safety, and effectiveness of AI and machine learning (ML) medical devices, the US Food and Drug Administration (FDA) has established regulatory guidelines to support the performance evaluation of medical devices. Furthermore, the FDA has proposed continuous surveillance requirements for AI/ML medical devices. This paper presents a summary of SaMD products that have passed the FDA 510 (k) AI/ML pathway, the challenges associated with the current AI/ML software-as-a-medical-device, and solutions for promoting the development of AI technologies in medicine. We hope to provide valuable information pertaining to medical-device design, development, and monitoring to ultimately achieve safer and more effective personalized medical services.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。